MedTrace Logo

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers

NCT04223895 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-01-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics and Safety/Tolerability of CKD-386

Conditions

  • Type2 Diabetes Mellitus

Interventions

DRUG

CKD-386 Formulation 1

A single oral dose of 1 tablet under fasting conditions for each period

DRUG

CKD-386 Formulation 2

A single oral dose of 1 tablet under fasting conditions for each period

DRUG

D012, D326 and D337

A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • 70-4665-9174 70-4665-9174 · H Plus Yangji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-03-04
Completion
2020-06-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04223895 on ClinicalTrials.gov